MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00911066
Recruitment Status : Completed
First Posted : June 1, 2009
Last Update Posted : December 5, 2013
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.